Product Description
AstraZeneca was developing azd-5658, an oral PI3K inhibitor, for the treatment of Type 2 Diabetics (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01176097)
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| D2920C00001 | P1 |
Completed |
Type 2 Diabetes |
2011-02-01 |
2019-03-19 |
Treatments |